Abstract：Schizophrenia is a group of serious mental diseases without specific causes, with a high prevalence rate, high disability rate and a heavy social burden. The global prevalence of schizophrenia is 1%. At present, antipsychotic drugs can well control the positive symptoms, but the negative symptoms and cognitive impairment of patients have not been effectively treated. Currently, it is generally believed that the defect of N-methyl D-aspartate receptor is the main cause of negative symptoms and cognitive impairment in patients with schizophrenia. Therefore, glutamate receptor has gradually become a key target for the development of a new generation of antipsychotic drugs. In this paper, we will summarize the progress of glutamate receptor-related drugs for schizophrenia in recent years in order to provide some suggestions for future clinic and researches in this field.
[1] 中华医学会精神病学分会. 精神分裂症防治指南[M].北京:北京大学医学出版社，2015：5.
[2] Patel R，Jayatilleke N，Broadbent M，et al. Negative symptoms in schizophrenia：a study in a large clinical sample of patients using a novel automated method [J]. BMJ Open，2015，5（9）：e007619.
[3] Jordan G，Lutgens D，Joober R，et al. The relative contribution of cognition and symptomatic remission to functional outcome following treatment of a first episode of psychosis [J]. J Clin Psychiatry，2014，75（6）：e566-e572.
[4] Krystal JH，Karper LP，Seibyl JP，et al. Subanesthetic effects of the noncompetitive NMDA antagonist，ketamine，in humans. Psychotomimetic，perceptual，cognitive，and neuroendocrine responses [J]. Arch Gen Psychiatry，1994，51（3）：199-214.
[5] Bergeron R，Meyer TM，Coyle JT，et al. Modulation of N-methyl-D-aspartate receptor function by glycine transport [J]. Proc Natl Acad Sci U S A，1998，95（26）：15 730-15 734.
[6] Buchanan RW，Javitt DC，Marder SR，et al. The Cognitive and Negative Symptoms in Schizophrenia Trial （CONSIST）：the efficacy of glutamatergic agents for negative symptoms and cognitive impairments [J]. Am J Psychiatry，2007，164（10）：1593-1602.
[7] Goff DC，Henderson DC，Evins AE，et al. A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia [J]. Biol Psychiatry，1999， 45（4）：512-514.
[8] Coyle J，Tsai G. The NMDA receptor glycine modulatory site：a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia [J]. Psychopharmacology （Berl），2003，174（1）.
[9] CioffiI CL. Glycine transporter-1 inhibitors：a patent review （2011-2016） [J]. Expert Opin Ther Pat，2018，28（3）：197-210.
[10] Bugarski-Kirola D，Iwata N，Sameljak S，et al. Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics：results from three phase 3，randomised，double-blind，parallel-group，placebo-controlled，multicentre studies in the SearchLyte clinical trial programme [J]. Lancet Psychiatry，2016，3（12）：1115-1128.
[11] Bugarski-Kirola D，Blaettler T，Arango C，et al. Bitopertin in Negative Symptoms of Schizophrenia-Results From the Phase Ⅲ FlashLyte and DayLyte Studies [J]. Biol Psychiatry，2017，82（1）：8-16.
[12] Madeira C，Freitas ME，Vargas-Lopes C，et al. Increased brain D-amino acid oxidase （DAAO） activity in schizophrenia [J]. Schizophr Res，2008，101（1-3）：76-83.
[13] Lane HY，Lin CH，Green MF，et al. Add-on treatment of benzoate for schizophrenia：a randomized，double-blind，placebo-controlled trial of D-amino acid oxidase inhibitor [J]. JAMA Psychiatry，2013，70（12）：1267-1275.
[14] Lin CH，Lin CH，Chang YC，et al. Sodium Benzoate，a D-Amino Acid Oxidase Inhibitor，Added to Clozapine for the Treatment of Schizophrenia：A Randomized，Double-Blind，Placebo-Controlled Trial [J]. Biol Psychiatry，2018， 84（6）：422-432.
[15] Isherwood SN，Robbins TW，Dalley JW，et al. Bidirectional variation in glutamate efflux in the medial prefrontal cortex induced by selective positive and negative allosteric mGluR5 modulators [J]. J Neurochem，2018， 145（2）：111-124.
[16] Ayala JE，Chen Y，Banko JL，et al. mGluR5 positive allosteric modulators facilitate both hippocampal LTP and LTD and enhance spatial learning [J]. Neuropsychopharmacology，2009，34（9）：2057-2071.
[17] Ayoub MA，Angelicheva D，Vile D，et al. Deleterious GRM1 mutations in schizophrenia[J]. PLoS One，2012，7（3）：e32849.
[18] Zhang H，Sulzer D. Glutamate spillover in the striatum depresses dopaminergic transmission by activating group I metabotropic glutamate receptors [J]. J Neurosci，2003， 23（33）：10 585-10 592.
[19] Satow A，Suzuki G，Maehara S，et al. Unique antipsychotic activities of the selective metabotropic glutamate receptor 1 allosteric antagonist 2-cyclopropyl-5-[1-（2-fluoro-3-pyridinyl）-5-methyl-1H-1，2，3-triazol-4-yl]-2，3-dih ydro-1H-isoindol-1-one [J]. J Pharmacol Exp Ther，2009，330（1）：179-190.
[20] Walker AG，Wenthur CJ，Xiang Z，et al. Metabotropic glutamate receptor 3 activation is required for long-term depression in medial prefrontal cortex and fear extinction [J]. Proc Natl Acad Sci U S A，2015，112（4）：1196-1201.
[21] Walker AG，Sheffler DJ，Lewis AS，et al. Co-Activation of Metabotropic Glutamate Receptor 3 and Beta-Adrenergic Receptors Modulates Cyclic-AMP and Long-Term Potentiation，and Disrupts Memory Reconsolidation [J]. Neuropsychopharmacology，2017，42（13）：2553-2566.
[22] Rosenberg N，Gerber U，Ster J. Activation of Group Ⅱ Metabotropic Glutamate Receptors Promotes LTP Induction at Schaffer Collateral-CA1 Pyramidal Cell Synapses by Priming NMDA Receptors [J]. J Neurosci，2016，36（45）：11521-11531.
[23] Homayoun H，Jackson ME，Moghaddam B. Activation of metabotropic glutamate 2/3 receptors reverses the effects of NMDA receptor hypofunction on prefrontal cortex unit activity in awake rats [J]. J Neurophysiol，2005，93（4）：1989-2001.
[24] Patil ST，Zhang L，Martenyi F，et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia：a randomized Phase 2 clinical trial[J]. Nat Med，2007，13（9）：1102-1107.
[25] Downing AM，Kinon BJ，Millen BA，et al. A Double-Blind，Placebo-Controlled Comparator Study of LY2140023 monohydrate in patients with schizophrenia[J]. BMC Psychiatry，2014，14：351.
[26] Jin LE，Wang M，Yang ST，et al. mGluR2/3 mechanisms in primate dorsolateral prefrontal cortex：evidence for both presynaptic and postsynaptic actions[J]. Mol Psychiatry，2017，22（11）：1615-1625.
[27] Saini SM，Mancuso SG，Mostaid MS，et al. Meta-analysis supports GWAS-implicated link between GRM3 and schizophrenia risk[J]. Transl Psychiatry，2017，7（8）：e1196.
[28] Fujioka R，Nii T，Iwaki A，et al. Comprehensive behavioral study of mGluR3 knockout mice：implication in schizophrenia related endophenotypes [J]. Mol Brain，2014， 7：31.
[29] Corti C，Battaglia G，Molinaro G，et al. The use of knock-out mice unravels distinct roles for mGlu2 and mGlu3 metabotropic glutamate receptors in mechanisms of neurodegeneration/neuroprotection[J]. J Neurosci，2007，27（31）：8297-8308.
[30] Di Menna L，Joffe ME，Iacovelli L，et al. Functional partnership between mGlu3 and mGlu5 metabotropic glutamate receptors in the central nervous system[J]. Neuropharmacology，2018，128：301-313.
[31] Kalinichev M，Le Poul E，Bolea C，et al. Characterization of the novel positive allosteric modulator of the metabotropic glutamate receptor 4 ADX88178 in rodent models of neuropsychiatric disorders[J]. J Pharmacol Exp Ther，2014，350（3）：495-505.
[32] Holscher C，Schmid S，Pilz PK，et al. Lack of the metabotropic glutamate receptor subtype 7 selectively impairs short-term working memory but not long-term memory[J]. Behav Brain Res，2004，154（2）：473-481.
[33] Gerlai R，Adams B，Fitch T，et al. Performance deficits of mGluR8 knockout mice in learning tasks：the effects of null mutation and the background genotype[J]. Neuropharmacology，2002，43（2）：235-249.
[34] Yin S，Noetzel MJ，Johnson KA，et al. Selective actions of novel allosteric modulators reveal functional heteromers of metabotropic glutamate receptors in the CNS[J]. J Neurosci，2014，34（1）：79-94.
2019, Vol. 16 
京公网安备 11010502046598号